Cellmid’s product development program is currently commercialising its midkine assets in three broad areas:
•
Midkine as a diagnostic marker for cancer
Midkine protein as a therapeutic to treat heart attack
Anti-midkine antibodies to treat the autoimmune diseases MS and RA
To view Cellmid’s complete product pipeline, click here.